HCA HCA Healthcare, Inc. Common Stock
NYSE · Health Care · عرض على SEC EDGAR ↗ إغلاق أكتوبر 2, 2026 10-K/10-Q يوليو 28, 2026HCA لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
HCA مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
تتكيف دقة الشريط مع الفترة المحددة - مرر مؤشر الفأرة فوق الرسم البياني لرؤية الافتتاح/الأعلى/الأدنى/الإغلاق للشريط.
حول HCA Healthcare, Inc. Common Stock نظرة عامة على الشركة من ويكيبيديا
HCA Healthcare, Inc. (historically known as Hospital Corporation of America) is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
History
Early years
The Hospital Corporation of America (HCA) was founded in 1968 in Nashville, Tennessee, by Thomas F. Frist Sr., Thomas F. Frist Jr. and Jack C. Massey. The founders envisioned a company that would bring together hospitals to deliver patient-focused care while using the combined resources of the organization to strengthen hospitals and improve the practice of medicine. The company began with Nashville's Park View Hospital, which the elder Frist had founded in 1960 with other doctors and where he was chief executive.
The company included 11 hospitals when it filed its initial public offering on the New York Stock Exchange (NYSE) in 1969 and had 26 hospitals and 3,000 beds by the end of the year.
Growth and merger
The 1970s were characterized by rapid growth in the industry and for HCA Healthcare. In the early 1980s, the focus shifted to consolidation with HCA Healthcare acquiring General Care Corporation, General Health Services, Hospital Affiliates International and Health Care Corporation. By the end of 1981, the company operated 349 hospitals with more than 49,000 beds. Operating revenues had grown to $2.4 billion.
In 1987, HCA Healthcare, which had grown to operate 463 hospitals (255 owned and 208 managed), spun off HealthTrust, a privately owned, 104-hospital company. Believing its stock was undervalued, the company completed a $5.1 billion leveraged management buyout led by chairman Thomas F. Frist Jr. in 1988. HCA Healthcare re-emerged as a public company in 1992.
In February 1994, HCA Healthcare merged with Louisville, Kentucky-based Columbia Hospital Corporation, which earlier had acquired 73 hospitals of Galen Health Care from Humana,
to form Columbia/HCA Healthcare Corporation. Related names of note include HCA International and Health Corporation of America.
Columbia Hospital Corporation
In 1988, Rick Scott and Richard Rainwater each put up $125,000 in working capital in their new company, Columbia Hospital Corporation; they borrowed the remaining money needed to purchase two struggling hospitals in El Paso for $60 million. Then they acquired a neighboring hospital and shut it down. Within a year, the remaining two were doing much better. By the end of 1989, Columbia Hospital Corporation owned four hospitals with a total of 833 beds.
In 1992, Columbia made a stock purchase of Basic American Medical, which owned eight hospitals, primarily in southwestern Florida. In September 1993, Columbia did another stock purchase, worth $3.4 billion, of Galen Healthcare, which had been spun off by Humana Inc. several months earlier. At the time, Galen had approximately 90 hospitals. After the purchase, Galen stockholders had 82% of the stock in the combined company, with Scott still running the company.
Recent history
On November 17, 2006, HCA became a private company for the third time when it completed a merger in which the company was acquired by a private investor group including affiliates of Kohlberg Kravis Roberts and Bain Capital, together with Merrill Lynch and HCA Healthcare founder Thomas F. Frist Jr. The total transaction was valued at approximately $33 billion, making it the largest leveraged buyout in history at the time, eclipsing the 1989 buyout of RJR Nabisco.
In May 2010, HCA announced that the corporation would once again go public with an expected $4.6-billion IPO as HCA Holdings, Inc. In March 2011, HCA sold 126.2 million shares for $30 each, raising about $3.79 billion, at that time, the largest private-equity backed IPO in U.S. history. In May 2017, the corporation was renamed HCA Healthcare.
In December 2018, a historical marker was installed in the parking lot of HCA's Sarah Cannon Cancer Center in Nashville, formerly the location of HCA's first hospital, Park View Hospital.
In 2018, the company was ranked No. 67 in the 2019 Fortune 500 list of the largest United States corporations by total revenue.
In May 2021, the company finalized a deal with Google to develop healthcare algorithms using patient records. In August 2021, HCA announced a deal with venture capital firm General Catalyst to develop digital solutions to streamline workflows and improve patient care; as part of the deal, HCA sold its healthcare app development firm PatientKeeper to General Catalyst's portfolio company Commure.
In April 2022, HCA Healthcare announced a $1.5 million partnership with Florida International University's Nicole Wertheim college of Nursing and Health Sciences, to expand its facilities to address the national nursing shortage.
In October 2022, LCMC Health in partnership with Tulane University announced that it would acquire Tulane Medical Center, Lakeview Regional Medical Center, and Tulane Lakeside Hospital from HCA for $150 million pending regulatory approval.
In March 2024, it was announced HCA had completed the sale of West Hills Hospital and Medical Center and related assets in Los Angeles, California to UCLA Health, for an undisclosed amount.
Facilities
United States
As of 2024, HCA has 186 hospitals. They also report operating more than 2,400 additional sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics located in 20 U.S. states and in the United Kingdom. A significant portion of those hospitals are situated in Florida and Texas. As of 2022, HCA had 47 hospitals and 31 surgery centers in Florida, and 45 hospitals and 632 affiliated sites of care in Texas. In 2021, it announced plans to build 3 new hospitals in Florida. In 2022, The Dallas Morning News reported that HCA will build 5 new hospitals in Texas. They also have a strong presence in Tennessee, where it began. HCA had 13 hospitals there as of 2019.
Between 2003 and 2017, HCA did not enter any new markets. However, in July 2007, HCA sold its hospitals in Switzerland.
In 2017, HCA acquired the Memorial University Medical Center in Savannah, Georgia. That same year, they acquired three Houston, Texas, hospitals from Tenet Healthcare.
In 2019 they purchased Mission Health System which operates hospitals in North Carolina.
In January 2020, HCA Healthcare acquired Valify, a healthcare cost-management company. In May 2020, HCA acquired 49-bed Shands Starke (Fla.) Regional Medical Center and 25-bed Shands Live Oak (Fla.) Regional Medical Center from CHS. HCA is operating the two facilities as off-campus emergency departments of Lake City (Fla.) Medical Center and North Florida Regional Medical Center in Gainesville. Later that year, it signed an agreement to sell Garden Park Medical Center to Singing River Health System.
In 2021, HCA sold Redmond Regional Medical Center to AdventHealth for $635M, and four other Georgia hospitals to Piedmont Healthcare for $950 million. They also announced the acquisition of Meadows Regional Medical Center.
United Kingdom
HCA International, the UK arm of Hospital Corporation of America, "caters for around half of all private patients in London." The main hospital sites within the United Kingdom it operates include:
It opened urgent care walk-in centres at London Bridge Hospital and the Portland Hospital in March 2018. It claims that patients, on average, wait just seven minutes to see a nurse and 17 minutes to see a doctor. In February 2022, outsourced cleaning staff at London Bridge Hospital reported a lack of PPE, no access to sick pay, a lack of training and no prior warning about which rooms may be contaminated with the virus through the COVID-19 pandemic.
The Princess Grace Hospital specializes in breast cancer and surgery, aided by Kefah Mokbel and Nick Perry who, in 2005, founded The London Breast Institute.
The company opened The Harborne Hospital, a newly built private hospital located close to the Queen Elizabeth Hospital, Birmingham, in February 2024.
Significant areas of operation
Medical education
In recent years, HCA Healthcare has become a significant provider of clinical and medical education. It is the largest sponsor of graduate medical education programs in the U.S., with 56 teaching hospitals in 14 states, primarily in regions with a deficit of physician training programs. The company includes Research College of Nursing and Mercy School of Nursing, and has several advanced nursing simulation training centers. In early 2020, it completed the purchase of a majority stake in Galen College of Nursing, which operates 21 campuses in 12 states, offering Bachelor of Science and Associate of Science nursing degrees.
Controversies
Medicare billing practices lawsuit
In 1993, lawsuits were filed against HCA by former employees who alleged that the company had engaged in questionable Medicare billing practices. In 1997, with a federal investigation by the FBI, the IRS and the Department of Health and Human Services in its early stages, the Columbia/HCA board of directors forced Rick Scott to resign as chairman and CEO amid growing evidence that the company "had kept two sets of books, one to show the government and one with actual expenses listed." Thomas Frist, a co-founder of HCA and brother of U.S. Senator Bill Frist, returned to the company as CEO in 1997 and called on longtime friend and colleague Jack O. Bovender Jr. to help him turn the company around.
The federal probe culminated in 2003 with "the government receiving a total of over $2 billion in criminal fines and civil penalties for systematically defrauding federal health care programs." Columbia/HCA pleaded guilty to 14 felonies and admitted to systematically overcharging the government. The federal probe has been referred to as the longest and costliest investigation for health-care fraud in U.S. history.
2005 insider trading suit
In July 2005, U.S. Senator Bill Frist sold all of his HCA shares, which were held in a blind trust, two weeks before disappointing earnings sent the stock on a 9-point plunge. At the time, Frist was considering a run for president and said that he had sold his shares to avoid the appearance of a conflict of interest. When the company disclosed that other executives had also sold their shares during that same time, shareholders alleged that the company had made false claims about its profits to drive up the price, which then fell when the company reported disappointing financial results. Eleven of HCA's senior officers were sued for accounting fraud and insider trading. HCA settled the lawsuit in August 2007, agreeing to pay $20 million to the shareholders but admitting no wrongdoing, and no charges were brought.
COVID-19 PPE
During the COVID-19 pandemic in the United States, HCA hospital nurses and other workers spoke out about the lack of PPE. In April 2020, there was an outcry against HCA following the deaths of two nurses Celia Yap-Banago and Rosa Luna who worked at HCA hospitals in Kansas City and California and had contracted coronavirus, despite the alarm having been raised about the lack of PPE at work.
Mission Hospital Acquisition Complaints
On December 14, 2023, the North Carolina Attorney General sued HCA for violating the terms of an agreement that allowed HCA to purchase Mission Health.
On February 13, 2024, HCA Healthcare denied the allegations and asked a judge to dismiss the lawsuit by the Attorney General, and in return the hospital network filed a counterclaim against the Attorney General.
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
| المقياس | اتجاه 5 سنوات | HCA | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| P/E (سنوي حالي) | 14.3متوسط 5 سنوات ≈13.8 | ≈13.8 | 16.5 | مقوّم بأقل من قيمته | |
| السعر/المبيعات (سنوي حالي) | 1.2متوسط 5 سنوات ≈1.2 | ≈1.2 | 1.2 | القيمة العادلة | |
| السعر / القيمة الدفترية (الربع الأخير) | -14.0متوسط 5 سنوات ≈-39.2 | ≈-39.2 | · | · | |
| EV / EBITDA | 38.7متوسط 5 سنوات ≈37.3 | ≈37.3 | 18.9 | مبالغ في تقييمه | |
| السعر / التدفق النقدي الحر (سنوي حالي) | 15.5متوسط 5 سنوات ≈14.6 | ≈14.6 | · | · | |
| السعر / التدفق النقدي (سنوي حالي) | 8.4متوسط 5 سنوات ≈7.9 | ≈7.9 | 9.1 | مقوّم بأقل من قيمته | |
| EV / Revenue (القيمة المؤسسية / الإيرادات) | 1.8متوسط 5 سنوات ≈1.8 | ≈1.8 | · | · | |
| EV / FCF (القيمة المؤسسية / التدفق النقدي الحر) | 17.7متوسط 5 سنوات ≈21.8 | ≈21.8 | · | · | |
| PEG Ratio (نسبة السعر إلى الأرباح إلى النمو (PEG)) | ≈0.7 | · | · | · |
يتم حساب الوسيط النظير على أساس موحد لكل مقياس وقد لا يتطابق دائمًا مع الأساس السنوي الحالي/الربع الأخير المعروض لهذا السهم.
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
| المقياس | اتجاه 5 سنوات | HCA | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| EBITDA Margin (هامش EBITDA) | 4.7%متوسط 5 سنوات ≈4.8% | ≈4.8% | 11.1% | ضعيف | |
| هامش ما قبل الضريبة (سنوي حالي) | 12.7%متوسط 5 سنوات ≈13.6% | ≈13.6% | 10.3% | من الدرجة الأولى | |
| هامش صافي الربح (سنوي حالي) | 8.8%متوسط 5 سنوات ≈9.3% | ≈9.3% | 7.3% | متوافق | |
| العائد على الأصول (سنوي حالي) | 11.1%متوسط 5 سنوات ≈11.2% | ≈11.2% | 6.5% | من الدرجة الأولى | |
| ROE (سنوي حالي) | -124.0%متوسط 5 سنوات ≈-963.7% | ≈-963.7% | 19.1% | ضعيف |
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
| المقياس | اتجاه 5 سنوات | HCA | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| الدين / حقوق الملكية (الربع الأخير) | -6.5متوسط 5 سنوات ≈-19.5 | ≈-19.5 | 0.1 | ديون منخفضة | |
| النسبة الحالية (الربع الأخير) | 1.0متوسط 5 سنوات ≈1.2 | ≈1.2 | 1.2 | سيولة منخفضة | |
| Quick Ratio (النسبة السريعة) | 0.7متوسط 5 سنوات ≈0.9 | ≈0.9 | 0.9 | سيولة منخفضة | |
| الدين طويل الأجل / حقوق الملكية (الربع الأخير) | -6.5متوسط 5 سنوات ≈-18.7 | ≈-18.7 | 0.1 | ديون منخفضة |
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
| المقياس | اتجاه 5 سنوات | HCA | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| Revenue YoY (الإيرادات مقارنة بالعام السابق) | 7.1%متوسط 5 سنوات ≈8.0% | ≈8.0% | · | · | |
| Revenue CAGR 3Y (معدل نمو الإيرادات السنوي المركب لـ 3 سنوات) | 7.9%متوسط 5 سنوات ≈7.4% | ≈7.4% | · | · | |
| Revenue CAGR 5Y (معدل نمو الإيرادات السنوي المركب لـ 5 سنوات) | 8.0% | · | · | · | |
| EPS YoY (ربحية السهم على أساس سنوي) | 28.8%متوسط 5 سنوات ≈25.6% | ≈25.6% | · | · | |
| Net Income YoY (صافي الدخل مقارنة بالعام السابق) | 17.8%متوسط 5 سنوات ≈17.4% | ≈17.4% | · | · | |
| EPS CAGR 3Y (متوسط نمو ربحية السهم السنوي لـ 3 سنوات) | 13.9%متوسط 5 سنوات ≈11.8% | ≈11.8% | · | · | |
| EPS CAGR 5Y (متوسط نمو ربحية السهم السنوي لـ 5 سنوات) | 21.0% | · | · | · | |
| Net Income CAGR 3Y (متوسط نمو صافي الدخل السنوي لـ 3 سنوات) | 6.3%متوسط 5 سنوات ≈4.0% | ≈4.0% | · | · | |
| Net Income CAGR 5Y (متوسط نمو صافي الدخل السنوي لـ 5 سنوات) | 12.6% | · | · | · |
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
| المقياس | اتجاه 5 سنوات | HCA | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| Asset Turnover (دوران الأصول) | 1.3متوسط 5 سنوات ≈1.2 | ≈1.2 | 0.8 | من الدرجة الأولى | |
| Receivables Turnover (دوران المستحقات) | 7.0متوسط 5 سنوات ≈7.1 | ≈7.1 | 8.3 | ضعيف | |
| Revenue / Employee (الإيرادات / الموظف) | ≈$328.7K | · | · | · |
القيمة · ≈ متوسط 5 سنوات · متوسط الصناعة · حكم مقارنة بالمتوسط
التوزيعات العائد، نسبة التوزيع، تاريخ توزيع الأرباح، معدل النمو السنوي المركب لمدة 5 سنوات
| تاريخ الاستحقاق | المبلغ | العملة | العائد |
|---|---|---|---|
| سبتمبر 16, 2026 | $0,78 | USD | ≈0.71% |
| يونيو 16, 2026 | $0,78 | USD | ≈0.76% |
| مارس 17, 2026 | $0,78 | USD | ≈0.58% |
| ديسمبر 15, 2025 | $0,72 | USD | ≈0.60% |
| سبتمبر 16, 2025 | $0,72 | USD | ≈0.71% |
| يونيو 16, 2025 | $0,72 | USD | ≈0.75% |
| مارس 17, 2025 | $0,72 | USD | ≈0.82% |
| ديسمبر 13, 2024 | $0,66 | USD | ≈0.84% |
| سبتمبر 16, 2024 | $0,66 | USD | ≈0.64% |
| يونيو 14, 2024 | $0,66 | USD | ≈0.75% |
| مارس 14, 2024 | $0,66 | USD | ≈0.76% |
| ديسمبر 13, 2023 | $0,60 | USD | ≈0.89% |
| سبتمبر 14, 2023 | $0,60 | USD | ≈0.90% |
| يونيو 15, 2023 | $0,60 | USD | ≈0.81% |
| مارس 16, 2023 | $0,60 | USD | ≈0.90% |
| ديسمبر 13, 2022 | $0,56 | USD | ≈0.92% |
| سبتمبر 15, 2022 | $0,56 | USD | ≈1.0% |
| يونيو 15, 2022 | $0,56 | USD | ≈1.1% |
| مارس 16, 2022 | $0,56 | USD | ≈0.75% |
| ديسمبر 13, 2021 | $0,48 | USD | ≈0.90% |
سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
| الفترة | تقرير | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|---|
| 30 يونيو، 2026 | يوليو 23, 2026 | $7.62 | $7.54 | 1.0% |
| 31 مارس، 2026 | $7.15 | $7.21 | -0.85% | |
| 31 ديسمبر، 2025 | $8.14 | $7.53 | 8.0% | |
| 30 سبتمبر، 2025 | $6.96 | $5.77 | 20.6% | |
| 30 يونيو، 2025 | $6.83 | $6.31 | 8.2% | |
| 31 مارس، 2025 | $6.45 | $5.84 | 10.5% |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| SG&A Expense | $548M | $421M | $353M | $307M | $337M | $416M | $370M | $344M | $340M | $343M | |
| Operating Expenses | $65.77B | $62.08B | $57.26B | $51.65B | $48.92B | $46.10B | $46.09B | $41.34B | $39.23B | $36.68B | |
| Interest Expense | $2.25B | $2.06B | $1.94B | $1.74B | $1.57B | $1.58B | $1.82B | $1.75B | $1.69B | $1.71B | |
| Pretax Income | $9.83B | $8.52B | $7.71B | $8.58B | $9.83B | $5.43B | $5.24B | $5.33B | $4.38B | $4.81B | |
| Income Tax | $2.05B | $1.87B | $1.61B | $1.75B | $2.11B | $1.04B | $1.10B | $946M | $1.64B | $1.38B | |
| Net Income | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| EPS (Basic) | $28.70 | $22.27 | $19.25 | $19.43 | $21.52 | $11.10 | $10.27 | $10.90 | $6.12 | $7.53 | |
| EPS (Diluted) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 | |
| Shares (Basic) | 236,413,000 | 258,603,000 | 272,404,000 | 290,348,000 | 323,315,000 | 338,274,000 | 341,210,000 | 347,297,000 | 362,305,000 | 383,591,000 | |
| Shares (Diluted) | 239,495,000 | 261,806,000 | 276,412,000 | 294,666,000 | 328,752,000 | 343,605,000 | 348,226,000 | 355,303,000 | 372,221,000 | 395,851,000 | |
| EBITDA | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B |
الميزانية العمومية
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.04B | $1.93B | $935M | $908M | $1.45B | $1.79B | $621M | $502M | $732M | $646M | |
| Short-term Investments | · | · | · | · | · | $116M | $147M | $47M | $54M | $49M | |
| Receivables | $10.87B | $10.75B | $9.96B | $8.89B | $8.10B | $7.05B | $7.38B | $6.79B | $6.50B | $5.83B | |
| Inventory | $1.65B | $1.74B | $2.02B | $2.07B | $1.99B | $2.02B | $1.85B | $1.73B | $1.57B | $1.50B | |
| Other Current Assets | $2.22B | $1.99B | $2.01B | $1.78B | $2.01B | $1.46B | $1.35B | $1.19B | $1.17B | $1.11B | |
| Current Assets | $15.78B | $16.41B | $14.93B | $13.64B | $13.54B | $12.33B | $11.20B | $10.21B | $9.98B | $9.09B | |
| PP&E (Net) | $31.14B | $29.41B | $27.71B | $25.57B | $24.06B | $23.20B | $22.71B | $19.76B | $17.89B | $16.35B | |
| PP&E (Gross) | $66.28B | $62.51B | $58.55B | $54.76B | $51.35B | $49.32B | $47.23B | $42.97B | $40.08B | $37.05B | |
| Accum. Depreciation | $35.13B | $33.10B | $30.83B | $29.18B | $27.29B | $26.12B | $24.52B | $23.21B | $22.19B | $20.70B | |
| Other Non-current Assets | $255M | $230M | $184M | $298M | $598M | $546M | $480M | $690M | $710M | $1.07B | |
| Total Assets | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Accounts Payable | $4.66B | $4.28B | $4.23B | $4.24B | $4.11B | $3.54B | $2.90B | $2.58B | $2.61B | $2.32B | |
| Current Liabilities | $16.35B | $15.18B | $12.65B | $9.90B | $9.58B | $8.70B | $7.76B | $7.57B | $6.16B | $5.83B | |
| Capital Leases | $1.85B | $1.86B | $1.90B | $1.75B | $1.75B | $1.67B | $1.50B | · | · | · | |
| Total Liabilities | · | · | · | · | · | · | $45.62B | $42.12B | $41.59B | $39.39B | |
| Long-term Debt | $44.28B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Total Debt | $41.60B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Retained Earnings | $-5.72B | $-2.12B | $-1.35B | $-2.28B | $-532M | $777M | $-2.35B | $-4.57B | $-6.53B | $-6.97B | |
| AOCI | $-305M | $-387M | $-425M | $-490M | $-404M | $-502M | $-460M | $-381M | $-278M | $-338M | |
| Stockholders' Equity | $-6.03B | $-2.50B | $-1.77B | $-2.77B | $-933M | $572M | $-2.81B | $-4.95B | $-6.81B | $-7.30B | |
| Liabilities + Equity | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Shares Outstanding | 224,605,100 | 249,981,400 | 265,537,300 | 277,378,300 | 305,476,800 | 339,425,600 | 338,445,600 | 342,895,200 | 350,091,600 | 370,535,900 |
التدفق النقدي
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B | |
| Stock-based Comp | $401M | $360M | $262M | $341M | $440M | $362M | $347M | $268M | $270M | $251M | |
| Amort. of Intangibles | $12M | $16M | $20M | $44M | $25M | $26M | · | · | · | · | |
| Other Non-cash | $1.93B | $1.08B | $850M | $-431M | $-1.29B | $2.40B | $1.07B | $461M | $-3.53B | $-2.67B | |
| Operating Cash Flow | $12.64B | $10.51B | $9.43B | $8.52B | $8.96B | $9.23B | $7.60B | $6.76B | $5.43B | $5.65B | |
| CapEx | $4.94B | $4.88B | $4.74B | $4.39B | $3.58B | $2.83B | $4.16B | $3.57B | $3.02B | $2.76B | |
| Investing Cash Flow | $-4.99B | $-4.93B | $-5.32B | $-3.39B | $-2.64B | $-3.39B | $-5.72B | $-3.90B | $-4.28B | $-3.24B | |
| Debt Issued | $8.47B | $7.50B | $3.22B | $6.00B | $4.34B | $2.70B | $6.45B | $2.00B | $1.50B | $5.40B | |
| Net Debt Issued | $1.08B | $5.08B | $2.31B | $3.17B | $475M | $-737M | $1.13B | $296M | $749M | $925M | |
| Stock Repurchased | $10.07B | $6.04B | $3.81B | $7.00B | $8.21B | $441M | $1.03B | $1.53B | $2.05B | $2.75B | |
| Net Stock Activity | $-10.07B | $-6.04B | $-3.81B | $-7.00B | $-8.21B | $-441M | $-1.03B | $-1.53B | $-2.05B | $-2.75B | |
| Dividends Paid | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · | |
| Financing Cash Flow | $-8.55B | $-4.58B | $-4.09B | $-5.66B | $-6.66B | $-4.68B | $-1.77B | $-3.08B | $-1.06B | $-2.51B | |
| Net Change in Cash | $-893M | $998M | $27M | $-543M | $-342M | $1.17B | $119M | $-230M | $86M | $-95M | |
| Taxes Paid | $1.74B | $1.84B | $1.39B | $1.18B | $2.18B | $1.00B | $849M | $872M | $1.21B | $1.25B | |
| Free Cash Flow | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B | $6.40B | $3.44B | $3.19B | $2.41B | $2.89B | |
| Levered FCF | $5.91B | $4.03B | $3.16B | $2.74B | $4.15B | $5.12B | $2.00B | $1.74B | $1.35B | $1.68B |
الربحية
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 9.0% | 8.2% | 8.1% | 9.4% | 11.8% | 7.3% | 6.8% | 8.1% | · | · | |
| Pretax Margin | 13.0% | 12.1% | 11.9% | 14.2% | 16.7% | 10.5% | 10.2% | 11.4% | · | · | |
| EBITDA Margin | 4.7% | 4.7% | 4.7% | 4.9% | 4.9% | 5.3% | 5.1% | 4.9% | · | · | |
| ROA | 11.3% | 10.0% | 9.7% | 10.9% | 14.2% | 8.1% | 8.3% | 10.0% | 6.3% | 8.7% | |
| ROE | -159.1% | -269.6% | -230.9% | -305.0% | -3853.7% | -335.8% | -90.4% | -64.4% | -31.4% | -38.8% |
السيولة والملاءة
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.3 | 1.6 | 1.6 | |
| Quick Ratio | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 | 1.0 | 1.1 | 1.0 | 1.2 | 1.1 | |
| Debt / Equity | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 | 54.2 | -12.0 | -6.6 | -4.9 | -4.3 | |
| LT Debt / Equity | -6.9 | -15.3 | -21.0 | -13.6 | -36.8 | 53.8 | -12.0 | -6.5 | -4.8 | -4.3 |
الكفاءة
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.3 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 1.2 | 1.2 | · | · | |
| Receivables Turnover | 7.0 | 6.8 | 6.9 | 7.1 | 7.8 | 7.1 | 7.2 | 7.0 | · | · |
لكل سهم
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-26.83 | $-10.00 | $-6.68 | $-9.98 | $-3.05 | $1.69 | $-8.30 | $-14.44 | $-19.44 | $-19.71 | |
| Revenue / Share | $315.66 | $269.68 | $235.04 | $204.41 | $178.71 | $149.98 | $147.42 | $131.37 | · | · | |
| Cash Flow / Share | $52.76 | $40.16 | $34.12 | $28.92 | $27.25 | $26.87 | $21.83 | $19.03 | $14.58 | $14.28 | |
| Cash / Share | $4.63 | $7.73 | $3.52 | $3.27 | $4.75 | $5.28 | $1.83 | $1.46 | $2.09 | $1.74 | |
| Dividend / Share | $2.88 | $2.64 | $2.40 | $2.24 | $1.92 | $0.43 | $1.60 | $1.40 | · | · | |
| EPS (TTM) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 |
معدلات النمو
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.1% | 8.7% | 7.9% | 2.5% | 14.0% | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.9% | 6.3% | 8.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.0% | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 28.8% | 16.0% | -0.94% | -9.5% | 93.6% | · | · | · | · | · | |
| EPS CAGR 3Y | 13.9% | 1.3% | 20.2% | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 21.0% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 17.8% | 9.9% | -7.1% | -18.9% | 85.3% | · | · | · | · | · | |
| Net Income CAGR 3Y | 6.3% | -6.1% | 11.8% | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 12.6% | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 34.7% | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا)
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| Net Income TTM | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| Market Cap | $104.86B | $75.03B | $71.88B | $66.56B | $78.48B | $55.82B | $50.03B | $42.67B | $30.75B | $27.43B | |
| Enterprise Value | $145.42B | $116.13B | $110.53B | $103.74B | $111.61B | $84.92B | $82.98B | $74.95B | $63.02B | $58.11B | |
| P/E | 16.5 | 13.6 | 14.3 | 12.5 | 12.1 | 15.0 | 14.7 | 11.7 | 14.8 | 10.1 | |
| P/S | 1.4 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.0 | 0.9 | 0.7 | 0.7 | |
| P/B | -17.4 | -30.0 | -40.5 | -24.1 | -84.1 | 97.6 | -17.8 | -8.6 | -4.5 | -3.8 | |
| P / Tangible Book | · | · | · | · | · | 97.6 | · | · | · | · | |
| P / Cash Flow | 8.3 | 7.1 | 7.6 | 7.8 | 8.8 | 6.0 | 6.6 | 6.3 | 5.7 | 4.9 | |
| P / FCF | 13.6 | 13.3 | 15.3 | 16.1 | 14.6 | 8.7 | 14.5 | 13.4 | 12.8 | 9.5 | |
| EV / EBITDA | 41.3 | 35.1 | 35.9 | 34.9 | 39.1 | 31.2 | 32.0 | 32.9 | 29.6 | 29.6 | |
| EV / FCF | 18.9 | 20.6 | 23.6 | 25.1 | 20.7 | 13.3 | 24.1 | 23.5 | 26.1 | 20.1 | |
| EV / Revenue | 1.9 | 1.6 | 1.7 | 1.7 | 1.9 | 1.6 | 1.6 | 1.6 | 1.4 | 1.4 | |
| Dividend Yield | 0.65% | 0.92% | 0.92% | 0.98% | 0.80% | 0.27% | 1.1% | 1.1% | 0.00% | · | |
| Earnings Yield | 6.1% | 7.3% | 7.0% | 8.0% | 8.2% | 6.7% | 6.8% | 8.6% | 6.8% | 9.9% | |
| Payout Ratio | 10.0% | 12.0% | 12.6% | 11.6% | 9.0% | 4.1% | 15.7% | 12.9% | · | · | |
| Annual Payout | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · |
قائمة الدخل
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.23B | $19.11B | $19.51B | $19.16B | $18.61B | $18.32B | $18.29B | $17.49B | $17.49B | $17.34B | $17.30B | $16.21B | $15.86B | $15.59B | $15.50B | $14.97B | |
| SG&A Expense | $148M | $133M | $153M | $139M | $130M | $126M | $120M | $111M | $100M | $90M | $108M | $89M | $82M | $74M | $79M | $74M | |
| Operating Expenses | $17.74B | $16.82B | $16.84B | $16.74B | $16.19B | $15.99B | $16.15B | $15.58B | $15.26B | $15.09B | $14.96B | $14.58B | $14.05B | $13.67B | $12.20B | $13.27B | |
| Interest Expense | $599M | $584M | $572M | $561M | $568M | $547M | $528M | $515M | $506M | $512M | $491M | $483M | $485M | $479M | $453M | $446M | |
| Pretax Income | $2.49B | $2.29B | $2.67B | $2.42B | $2.42B | $2.33B | $2.13B | $1.91B | $2.24B | $2.25B | $2.35B | $1.63B | $1.81B | $1.92B | $3.30B | $1.70B | |
| Income Tax | $564M | $430M | $509M | $515M | $524M | $502M | $447M | $424M | $550M | $445M | $484M | $355M | $397M | $379M | $656M | $360M | |
| Net Income | $1.70B | $1.62B | $1.88B | $1.64B | $1.65B | $1.61B | $1.44B | $1.27B | $1.46B | $1.59B | $1.61B | $1.08B | $1.19B | $1.36B | $2.08B | $1.13B | |
| EPS (Basic) | $7.70 | $7.25 | $8.22 | $7.05 | $6.91 | $6.52 | $5.72 | $4.94 | $5.60 | $6.01 | $6.00 | $3.98 | $4.35 | $4.92 | $7.30 | $3.97 | |
| EPS (Diluted) | $7.62 | $7.15 | $8.09 | $6.96 | $6.83 | $6.45 | $5.66 | $4.88 | $5.53 | $5.93 | $5.92 | $3.91 | $4.29 | $4.85 | $7.20 | $3.91 | |
| Shares (Basic) | 220,538,000 | 223,588,000 | · | 232,891,000 | 239,173,000 | 246,936,000 | · | 256,763,000 | 261,156,000 | 264,435,000 | · | 271,173,000 | 274,494,000 | 276,910,000 | · | 285,958,000 | |
| Shares (Diluted) | 222,828,000 | 226,652,000 | · | 236,181,000 | 241,911,000 | 249,440,000 | · | 259,917,000 | 264,071,000 | 268,016,000 | · | 275,424,000 | 278,198,000 | 280,961,000 | · | 289,852,000 | |
| EBITDA | $944M | $930M | · | $889M | $863M | $860M | · | $842M | $819M | $795M | · | $769M | $763M | $756M | · | $749M |
الميزانية العمومية
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.01B | $940M | $1.04B | $997M | $939M | $1.06B | $1.93B | $2.89B | $831M | $1.28B | · | $891M | $862M | $842M | · | $999M | |
| Receivables | $12.28B | $11.32B | $10.87B | $10.43B | $10.46B | $11.09B | $10.75B | $9.91B | $10.24B | $10.04B | · | $9.18B | $8.71B | $8.66B | · | $8.55B | |
| Inventory | $1.66B | $1.68B | $1.65B | $1.73B | $1.79B | $1.79B | $1.74B | $1.78B | $1.80B | $1.90B | · | $2.03B | $2.05B | $2.08B | · | $2.01B | |
| Other Current Assets | $2.23B | $2.11B | $2.22B | $2.13B | $2.37B | $2.32B | $1.99B | $2.08B | $2.30B | $2.05B | · | $2.19B | $2.26B | $1.96B | · | $1.92B | |
| Current Assets | $17.19B | $16.05B | $15.78B | $15.29B | $15.56B | $16.26B | $16.41B | $16.66B | $15.17B | $15.28B | · | $14.29B | $13.89B | $13.54B | · | $13.48B | |
| PP&E (Net) | $31.82B | $31.47B | $31.14B | $30.57B | $30.12B | $29.74B | $29.41B | $29.05B | $28.64B | $28.10B | · | $27.12B | $26.64B | $26.05B | · | $24.98B | |
| PP&E (Gross) | $68.41B | $67.36B | $66.28B | $65.49B | $64.39B | $63.68B | $62.51B | $61.75B | $60.62B | $59.44B | · | $57.77B | $56.67B | $55.46B | · | $53.73B | |
| Accum. Depreciation | $36.59B | $35.89B | $35.13B | $34.92B | $34.27B | $33.94B | $33.10B | $32.70B | $31.99B | $31.34B | · | $30.66B | $30.02B | $29.41B | · | $28.75B | |
| Other Non-current Assets | $258M | $326M | $255M | $277M | $236M | $226M | $230M | $309M | $240M | $199M | · | $200M | $196M | $319M | · | $461M | |
| Total Assets | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | $56.21B | $54.59B | $53.59B | $52.71B | $52.44B | $51.48B | |
| Accounts Payable | $4.75B | $4.81B | $4.66B | $4.55B | $4.25B | $4.49B | $4.28B | $4.24B | $4.03B | $4.74B | · | $4.14B | $3.82B | $3.77B | · | $4.16B | |
| Current Liabilities | $17.31B | $19.26B | $16.35B | $17.90B | $15.94B | $13.63B | $15.18B | $14.90B | $14.30B | $13.14B | · | $12.41B | $11.54B | $11.03B | · | $9.78B | |
| Capital Leases | $1.83B | $1.82B | $1.85B | $1.84B | $1.88B | $1.86B | $1.86B | $1.92B | $1.89B | $1.91B | · | $1.78B | $1.81B | $1.72B | · | $1.76B | |
| Long-term Debt | $45.83B | $44.37B | $44.28B | $42.60B | $42.70B | $44.58B | $43.03B | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Total Debt | $43.45B | $39.49B | · | $38.40B | $39.38B | $44.58B | · | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Retained Earnings | $-6.31B | $-5.98B | $-5.72B | $-5.02B | $-4.09B | $-3.16B | $-2.12B | $-1.81B | $-1.17B | $-1.19B | · | $-1.99B | $-1.85B | $-2.03B | · | $-2.78B | |
| AOCI | $-334M | $-327M | $-305M | $-317M | $-309M | $-357M | $-387M | $-378M | $-433M | $-433M | $-425M | $-491M | $-456M | $-470M | $-490M | $-592M | |
| Stockholders' Equity | $-6.64B | $-6.30B | $-6.03B | $-5.33B | $-4.39B | $-3.52B | $-2.50B | $-2.18B | $-1.60B | $-1.61B | · | $-2.48B | $-2.30B | $-2.50B | · | $-3.37B | |
| Liabilities + Equity | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | · | $54.59B | $53.59B | $52.71B | · | $51.48B | |
| Shares Outstanding | 217,963,300 | 222,530,900 | 224,605,100 | 229,845,100 | 236,143,900 | 242,955,400 | 249,981,400 | 254,517,700 | 259,237,600 | 263,215,800 | · | 268,967,300 | 272,931,700 | 275,939,900 | · | 283,903,500 |
التدفق النقدي
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $944M | $930M | $911M | $889M | $863M | $860M | $856M | $842M | $819M | $795M | $789M | $769M | $763M | $756M | $750M | $749M | |
| Stock-based Comp | $85M | $86M | $100M | $104M | $99M | $98M | $85M | $76M | $112M | $87M | $57M | $72M | $56M | $77M | $83M | $87M | |
| Other Non-cash | · | $-622M | · | · | · | $-917M | · | · | · | $-4M | · | · | · | $-393M | · | · | |
| Operating Cash Flow | $2.33B | $2.01B | $2.36B | $4.42B | $4.21B | $1.65B | $2.56B | $3.52B | $1.97B | $2.47B | $2.67B | $2.48B | $2.48B | $1.80B | $2.53B | $3.02B | |
| CapEx | $1.23B | $1.12B | $1.49B | $1.29B | $1.18B | $991M | $1.28B | $1.19B | $1.28B | $1.12B | $1.16B | $1.15B | $1.24B | $1.20B | $1.32B | $1.13B | |
| Investing Cash Flow | $-1.56B | $-1.28B | $-1.32B | $-1.39B | $-1.25B | $-1.03B | $-1.35B | $-1.35B | $-1.33B | $-903M | $-1.60B | $-1.31B | $-1.26B | $-1.15B | $-793M | $-546M | |
| Debt Issued | $2.99B | $0 | $3.24B | $0 | $0 | $5.23B | $0 | $3.01B | $0 | $4.48B | $4M | $2M | $3.22B | $0 | $21M | $10M | |
| Net Debt Issued | · | $-58M | · | · | · | $1.34B | · | · | · | $2.42B | · | · | · | $-550M | · | · | |
| Stock Repurchased | $2.06B | $1.57B | $2.56B | $2.50B | $2.50B | $2.51B | $1.70B | $1.79B | $1.37B | $1.18B | $910M | $1.14B | $915M | $846M | $1.52B | $698M | |
| Net Stock Activity | · | $-1.57B | · | · | · | $-2.51B | · | · | · | $-1.18B | · | · | · | $-846M | · | · | |
| Dividends Paid | $171M | $183M | $162M | $166M | $171M | $180M | $165M | $169M | $171M | $185M | $160M | $162M | $164M | $175M | $156M | $160M | |
| Financing Cash Flow | $-704M | $-830M | $-999M | $-2.97B | $-3.09B | $-1.50B | $-2.16B | $-110M | $-1.09B | $-1.22B | $-1.04B | $-1.13B | $-1.20B | $-725M | $-1.84B | $-2.32B | |
| Net Change in Cash | $73M | $-100M | $43M | $58M | $-121M | $-873M | $-955M | $2.06B | $-453M | $349M | $44M | $29M | $20M | $-66M | $-91M | $141M | |
| Taxes Paid | $730M | $-5M | $1.51B | $81M | $136M | $10M | $358M | $487M | $998M | $1M | $316M | $297M | $766M | $7M | $244M | $322M | |
| Free Cash Flow | · | $895M | · | · | · | $660M | · | · | · | $1.35B | · | · | · | $606M | · | · | |
| Levered FCF | · | $421M | · | · | · | $231M | · | · | · | $940M | · | · | · | $221M | · | · |
الربحية
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 8.4% | 8.5% | · | 8.6% | 8.9% | 8.8% | · | 7.3% | 8.3% | 9.2% | · | 6.7% | 7.5% | 8.7% | · | 7.6% | |
| Pretax Margin | 12.3% | 12.0% | · | 12.6% | 13.0% | 12.7% | · | 10.9% | 12.8% | 13.0% | · | 10.1% | 11.4% | 12.3% | · | 11.4% | |
| EBITDA Margin | 4.7% | 4.9% | · | 4.6% | 4.6% | 4.7% | · | 4.8% | 4.7% | 4.6% | · | 4.7% | 4.8% | 4.9% | · | 5.0% | |
| ROA | 2.8% | 2.7% | · | 2.8% | 2.8% | 2.8% | · | 2.2% | 2.6% | 2.9% | · | 2.0% | 2.3% | 2.6% | · | 2.2% | |
| ROE | -30.8% | -33.0% | · | -43.7% | -55.2% | -62.7% | · | -54.5% | -74.9% | -77.4% | · | -36.9% | -39.9% | -60.2% | · | -55.8% |
السيولة والملاءة
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.8 | · | 0.9 | 1.0 | 1.2 | · | 1.1 | 1.1 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.4 | |
| Quick Ratio | 0.8 | 0.6 | · | 0.6 | 0.7 | 0.9 | · | 0.9 | 0.8 | 0.9 | · | 0.8 | 0.8 | 0.9 | · | 1.0 | |
| Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -12.7 | · | -19.7 | -25.6 | -24.9 | · | -15.9 | -16.9 | -15.6 | · | -11.2 | |
| LT Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -11.7 | · | -17.5 | -22.7 | -23.0 | · | -14.9 | -15.9 | -14.6 | · | -11.1 |
الكفاءة
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| Receivables Turnover | 1.8 | 1.7 | · | 1.9 | 1.8 | 1.7 | · | 1.8 | 1.8 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
لكل سهم
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-30.47 | $-28.32 | · | $-23.21 | $-18.61 | $-14.48 | · | $-8.57 | $-6.17 | $-6.14 | · | $-9.21 | $-8.44 | $-9.04 | · | $-11.87 | |
| Revenue / Share | $90.79 | $84.31 | · | $81.13 | $76.91 | $73.45 | · | $67.28 | $66.24 | $64.69 | · | $58.87 | $57.01 | $55.49 | · | $51.65 | |
| Cash Flow / Share | · | $8.89 | · | · | · | $6.62 | · | · | · | $9.21 | · | · | · | $6.42 | · | · | |
| Cash / Share | $4.65 | $4.22 | · | $4.34 | $3.98 | $4.36 | · | $11.35 | $3.21 | $4.88 | · | $3.31 | $3.16 | $3.05 | · | $3.52 | |
| Dividend / Share | $0.78 | $0.78 | $0.72 | $0.72 | $0.72 | $0.72 | $0.66 | $0.66 | $0.66 | $0.66 | $0.60 | $0.60 | $0.60 | $0.60 | $0.56 | $0.56 | |
| EPS (TTM) | $29.82 | $29.03 | · | $25.90 | $23.82 | $22.52 | · | $22.26 | $21.29 | $20.05 | · | $20.25 | $20.25 | $19.86 | · | $17.61 |
التقييم (آخر 12 شهرًا)
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $78.01B | $76.39B | · | $74.37B | $72.70B | $71.58B | · | $69.62B | $68.35B | $66.72B | · | $63.16B | $61.92B | $60.88B | · | $59.80B | |
| Net Income TTM | $6.84B | $6.79B | · | $6.34B | $5.97B | $5.78B | · | $5.93B | $5.74B | $5.47B | · | $5.72B | $5.77B | $5.73B | · | $5.38B | |
| Market Cap | $84.98B | $105.31B | · | $97.96B | $90.47B | $83.95B | · | $103.44B | $83.29B | $87.79B | · | $66.16B | $82.83B | $72.76B | · | $52.18B | |
| Enterprise Value | $127.42B | $143.86B | · | $135.36B | $128.91B | $127.47B | · | $143.52B | $123.34B | $126.70B | · | $104.62B | $120.90B | $110.77B | · | $88.89B | |
| P/E | 13.1 | 16.3 | · | 16.5 | 16.1 | 15.3 | · | 18.3 | 15.1 | 16.6 | · | 12.1 | 15.0 | 13.3 | · | 10.4 | |
| P/S | 1.1 | 1.4 | · | 1.3 | 1.2 | 1.2 | · | 1.5 | 1.2 | 1.3 | · | 1.0 | 1.3 | 1.2 | · | 0.9 | |
| P/B | -12.8 | -16.7 | · | -18.4 | -20.6 | -23.9 | · | -47.4 | -52.1 | -54.4 | · | -26.7 | -36.0 | -29.2 | · | -15.5 | |
| P / Cash Flow | · | 52.3 | · | · | · | 50.8 | · | · | · | 35.6 | · | · | · | 40.4 | · | · | |
| EV / Revenue | 1.6 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.1 | 1.8 | 1.9 | · | 1.7 | 2.0 | 1.8 | · | 1.5 | |
| Dividend Yield | 0.80% | 0.65% | · | 0.70% | 0.76% | 0.82% | · | 0.66% | 0.81% | 0.76% | · | 0.99% | 0.79% | 0.89% | · | 1.2% | |
| Earnings Yield | 7.6% | 6.1% | · | 6.1% | 6.2% | 6.5% | · | 5.5% | 6.6% | 6.0% | · | 8.2% | 6.7% | 7.5% | · | 9.6% | |
| Payout Ratio | · | 11.3% | · | · | · | 11.2% | · | · | · | 11.6% | · | · | · | 12.8% | · | · | |
| Annual Payout | $682M | $682M | · | $682M | $685M | $685M | · | $685M | $678M | $671M | · | $657M | $655M | $651M | · | $645M |
أحدث فترة على اليسار · القيم الفارغة معروضة كـ ·
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
| المقياس | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| الإيرادات | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B |
| صافي الدخل | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B |
| EPS المخفف | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 |
| المقياس | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| الدين / حقوق الملكية | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 |
| النسبة الحالية | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 |
| النسبة السريعة | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 |
| المقياس | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| التدفق النقدي الحر | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B |
الملاك المؤسسيون (13F) 1473 مقدمي إقرار · $57.3B إجمالي · حتى تاريخ 30 سبتمبر، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 121 (-64 مقابل الربع السابق) | 176 (+72 مقابل الربع السابق) | 458 (-25 مقابل الربع السابق) | 581 (+4 مقابل الربع السابق) | -627K |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6870392526 | 14716173 | 12,00% | الأسهم |
| BlackRock, Inc. | $5069973824 | 13003600 | 8,85% | الأسهم |
| VANGUARD CAPITAL MANAGEMENT LLC | $3954150533 | 10141708 | 6,91% | الأسهم |
| Sanders Capital, LLC | $3442060818 | 8828287 | 6,01% | الأسهم |
| STATE STREET CORP | $2912102056 | 7469035 | 5,09% | الأسهم |
| WELLINGTON MANAGEMENT GROUP LLP | $1835396649 | 4707473 | 3,21% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $1423654808 | 3668008 | 2,49% | الأسهم |
| First Eagle Investment Management, LLC | $1284907912 | 3295565 | 2,24% | الأسهم |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1057704509 | 2712828 | 1,85% | الأسهم |
| MORGAN STANLEY | $1008556857 | 2586771 | 1,76% | الأسهم |
| GOLDMAN SACHS GROUP INC | $960811481 | 2464314 | 1,68% | الأسهم |
| JPMORGAN CHASE & CO | $896800955 | 2285832 | 1,57% | الأسهم |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $861456107 | 2209485 | 1,50% | الأسهم |
| NORGES BANK | $836457140 | 2145367 | 1,46% | الأسهم |
| Capital World Investors | $770864224 | 1977121 | 1,35% | الأسهم |
| Capital International Investors | $747403041 | 1916947 | 1,31% | الأسهم |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $709859997 | 1500000 | 1,24% | الأسهم |
| NORTHERN TRUST CORP | $666150458 | 1708560 | 1,16% | الأسهم |
| FMR LLC | $636503475 | 1632520 | 1,11% | الأسهم |
| Invesco Ltd. | $596390232 | 1529637 | 1,04% | الأسهم |
| NORDEA INVESTMENT MANAGEMENT AB | $553702529 | 1429943 | 0,97% | الأسهم |
| BARCLAYS PLC | $514349127 | 1319216 | 0,90% | الأسهم |
| JANUS HENDERSON GROUP PLC | $481486890 | 1017441 | 0,84% | الأسهم |
| Crake Asset Management LLP | $449072183 | 1151792 | 0,78% | الأسهم |
| Metropolis Capital Ltd | $430915307 | 910564 | 0,75% | الأسهم |
| Darsana Capital Partners LP | $428879000 | 1100000 | 0,75% | الأسهم |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $414565358 | 1063288 | 0,72% | الأسهم |
| Legal & General Group Plc | $410992402 | 1054124 | 0,72% | الأسهم |
| FRANKLIN RESOURCES INC | $399958688 | 1025824 | 0,70% | الأسهم |
| Life Cycle Investment Partners Ltd | $355737196 | 912404 | 0,62% | الأسهم |
| Bank of New York Mellon Corp | $350359895 | 898612 | 0,61% | الأسهم |
| VANGUARD FIDUCIARY TRUST CO | $339685814 | 871235 | 0,59% | الأسهم |
| ROYAL BANK OF CANADA | $320194000 | 821241 | 0,56% | الأسهم |
| LYRICAL ASSET MANAGEMENT LP | $255015742 | 654071 | 0,45% | الأسهم |
| BANK OF AMERICA CORP /DE/ | $238456934 | 611601 | 0,42% | الأسهم |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $237236367 | 608470 | 0,41% | الأسهم |
| ROYAL LONDON ASSET MANAGEMENT LTD | $235649908 | 604401 | 0,41% | الأسهم |
| PRINCIPAL FINANCIAL GROUP INC | $234827401 | 602290 | 0,41% | الأسهم |
| UBS Group AG | $230953291 | 592355 | 0,40% | الأسهم |
| National Pension Service | $230650346 | 591578 | 0,40% | الأسهم |
| Russell Investments Group, Ltd. | $206832565 | 530340 | 0,36% | الأسهم |
| Nuveen, LLC | $199595109 | 511927 | 0,35% | الأسهم |
| Gobi Capital LLC | $195742325 | 502045 | 0,34% | الأسهم |
| Cryder Capital Partners LLP | $194561738 | 499017 | 0,34% | الأسهم |
| Allianz Asset Management GmbH | $181127299 | 464560 | 0,32% | الأسهم |
| DEUTSCHE BANK AG\ | $175985429 | 451372 | 0,31% | الأسهم |
| Swiss National Bank | $172097446 | 441400 | 0,30% | الأسهم |
| DIMENSIONAL FUND ADVISORS LP | $172079393 | 441313 | 0,30% | الأسهم |
| AustralianSuper Pty Ltd | $159635782 | 409438 | 0,28% | الأسهم |
| HSBC HOLDINGS PLC | $158555065 | 406750 | 0,28% | الأسهم |
الناشطون والمالكون بنسبة 5%+ 4 حيازات
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| Frisco Holding II, Hercules Holding II, Thomas F. Frist, Jr., Thomas F. Frist III, William R. Frist, Patricia F. Elcan | 10 فبراير، 2026 | 31,60% | إيداع أولي | · | SEC |
| 22 نوفمبر، 2006 | · | إيداع أولي | · | SEC | |
| Merrill Lynch Bank USA | 11 سبتمبر، 2006 | · | إيداع أولي | · | SEC |
| Frisco, Inc., Frisco Partners, Thomas F. Frist, Jr., Patricia Champion Frist, Patricia Frist Elcan, William Robert Frist, Thomas F. Frist III, Merrill Lynch Professional Clearing Corp., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Merrill Lynch Financial Markets, Inc., Merrill Lynch International, Merrill Lynch & Co., Inc., Merrill Lynch Trust Company, FSB, Citigroup Inc.*, Bank of America Corporation, NB Holdings Corporation, NationsBanc Montgomery Holdings Corporation, Banc of America Securities LLC | 4 أغسطس، 2006 | · | إيداع أولي | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
المطلعون على الشركة 92 من المطلعين · مسؤولون 54 · مديرون 31
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Samuel N Hazen | CEO | 10 فبراير، 2026 F | 64842 | 0 | 7 | $-21483290 |
| O'Boyle Michael P | President & CEO - Parallon | 26 فبراير، 2013 A | 21429 | 0 | 0 | $0 |
| Mike A Marks | EVP and CFO | 7 مايو، 2026 G | 46576 | 0 | 0 | $0 |
| Bill B Rutherford | CFO and EVP | 16 فبراير، 2024 F | 22251 | 0 | 0 | $0 |
| Russell K Harms | CFO - Central Group | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| Robert Samuel Hankins JR | CFO-Outpatient Services Group | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| Richard J Shallcross | CFO - Western Group | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| Jeffrey T Crudele | CFO-Eastern Division | 1 يوليو، 2005 F | 13865 | 0 | 0 | $0 |
| Erol R Akdamar | Group President | 12 نوفمبر، 2024 M | 6843 | 0 | 0 | $0 |
| Timothy M Mcmanus | Group President | 31 يوليو، 2024 M | 27008 | 0 | 0 | $0 |
| Richard A Hammett | Group President | 16 فبراير، 2024 F | 17936 | 0 | 0 | $0 |
| Charles J Hall | Group President | 11 نوفمبر، 2022 M | 202443 | 0 | 0 | $0 |
| Bruce A Moore JR | Group President - Service Line | 11 نوفمبر، 2022 S | 30807 | 0 | 0 | $0 |
| Paul W Rutledge | Group President | 31 ديسمبر، 2012 A | 335657 | 0 | 0 | $0 |
| Beverly B Wallace | President - Parallon | 2 نوفمبر، 2011 M | 144714 | 0 | 0 | $0 |
| Charles Robert Evans | President - Eastern Group | 26 يوليو، 2006 A | 62173 | 0 | 0 | $0 |
| Marilyn B Tavenner | President-Outpatient Svcs Grp | 27 أكتوبر، 2005 A | 26154 | 0 | 0 | $0 |
| Greg Roth | President-Ambulatory Surgery | 31 أكتوبر، 2004 D | 9029 | 0 | 0 | $0 |
| Jay Grinney | President-Eastern Group | 7 مايو، 2004 D | 24177 | 0 | 0 | $0 |
| Jon M Foster | EVP and COO | 10 فبراير، 2026 F | 23062 | 0 | 0 | $0 |
| Michael R Mcalevey | EVP & Chief Legal & Admin Off. | 26 أغسطس، 2026 J | 0 | 0 | 2 | $-2747520 |
| Jennifer Berres | SVP & Chief Human Res. Officer | 11 فبراير، 2026 S | 11993 | 0 | 2 | $-4126932 |
| Christopher F. Wyatt | SVP & Controller | 11 فبراير، 2026 S | 44379 | 0 | 1 | $-2020000 |
| Erica Rossitto | SVP & Chief Nurse Executive | 10 فبراير، 2026 F | 10407 | 0 | 0 | $0 |
| Michael S. Cuffe | EVP and Chief Clinical Officer | 10 فبراير، 2026 F | 32080 | 0 | 1 | $-747135 |
| Sammie S Mosier | SVP & Chief Nurse Executive | 13 فبراير، 2025 F | 11113 | 0 | 0 | $0 |
| Kathleen M Whalen | SVP & Chief Ethics Officer | 14 نوفمبر، 2024 S | 9454 | 0 | 0 | $0 |
| Phillip G Billington | SVP-Internal Audit Services | 12 نوفمبر، 2024 M | 52702 | 0 | 0 | $0 |
| Joseph A Sowell III | SVP; Chief Development Officer | 5 أغسطس، 2024 G | 18526 | 0 | 0 | $0 |
| Deborah M Reiner | SVP - Mktg. & Communications | 29 يوليو، 2024 S | 3510 | 0 | 0 | $0 |
| Kathryn A. Torres | SVP-Payer Contracting & Align. | 25 يوليو، 2024 S | 17755 | 0 | 0 | $0 |
| Jeffrey E. Cohen | SVP-Government Relations | 9 مايو، 2024 S | 5185 | 0 | 0 | $0 |
| Chad J Wasserman | SVP and CIO | 18 مارس، 2024 M | 1576 | 0 | 0 | $0 |
| Martin P. Paslick | SVP and CIO | 12 إبريل، 2023 M | 24643 | 0 | 0 | $0 |
| Jane D. Englebright | SVP and Chief Nursing Officer | 9 نوفمبر، 2021 S | 0 | 0 | 0 | $0 |
| Robert A Waterman | SVP & General Counsel | 5 مايو، 2021 S | 50062 | 0 | 0 | $0 |
| William J Morrow | SVP - Finance and Treasurer | 18 فبراير، 2021 F | 5578 | 0 | 0 | $0 |
| Sandra L. Morgan | SVP-Provider Relations | 18 فبراير، 2021 F | 10122 | 0 | 0 | $0 |
| Victor L Campbell | SVP-Government Affairs | 1 مايو، 2019 A | 194145 | 0 | 0 | $0 |
| John M Steele | SVP & Chief Human Res. Officer | 25 فبراير، 2019 M | 84157 | 0 | 0 | $0 |
| Milton R Johnson | Chairman | 25 فبراير، 2019 M | 881823 | 0 | 0 | $0 |
| Ravi S. Chari | SVP-Clinical Excellence | 25 فبراير، 2018 M | 7003 | 0 | 0 | $0 |
| Alan R Yuspeh | SVP & Chief Ethics Officer | 25 فبراير، 2018 M | 35546 | 0 | 0 | $0 |
| Joseph N Steakley | SVP-Internal Audit Services | 25 فبراير، 2018 M | 65199 | 0 | 0 | $0 |
| Jana Joustra Davis | SVP - Mktg. & Corp. Affairs | 23 مايو، 2017 M | 26378 | 0 | 0 | $0 |
| David Gwin Anderson | SVP - Finance | 7 نوفمبر، 2016 M | 110167 | 0 | 0 | $0 |
| Donald W Stinnett | SVP & Controller | 25 فبراير، 2016 A | 51965 | 0 | 0 | $0 |
| Noel B Williams | SVP and CIO | 16 مايو، 2012 M | 299030 | 0 | 0 | $0 |
| Jack O Bovender JR | Chairman | 6 أكتوبر، 2009 A | 188340 | 0 | 0 | $0 |
| Carl V George | SVP - Development | 27 فبراير، 2009 M | 13092 | 0 | 0 | $0 |
| Patricia T Lindler | SVP - Government Programs | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| Rosalyn S Elton | SVP-Operations Finance | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| Frank M Houser MD | SVP-Quality & Medical Director | 26 يوليو، 2006 A | 46145 | 0 | 0 | $0 |
| James A Fitzgerald JR | SVP-Supply Chain Operations | 29 يناير، 2006 F | 20674 | 0 | 0 | $0 |
| Andrea B Smith | مدير | 28 إبريل، 2026 A | 4666 | 0 | 0 | $0 |
| William R Frist | مدير | 28 إبريل، 2026 A | 13740 | 0 | 0 | $0 |
| Wayne Joseph Riley | مدير | 28 إبريل، 2026 A | 15029 | 0 | 0 | $0 |
| Hugh F Johnston | مدير | 28 إبريل، 2026 A | 4475 | 0 | 0 | $0 |
| Thomas F Frist III | مدير | 28 إبريل، 2026 A | 15858 | 0 | 0 | $0 |
| Michael W Michelson | مدير | 28 إبريل، 2026 A | 12576 | 0 | 0 | $0 |
| Nancy Ann Deparle | مدير | 28 إبريل، 2026 A | 21910 | 0 | 0 | $0 |
| John Chidsey | مدير | 28 إبريل، 2026 A | 1305 | 0 | 0 | $0 |
| Robert J Dennis | مدير | 29 إبريل، 2025 A | 26601 | 0 | 0 | $0 |
| Meg Crofton | مدير | 29 إبريل، 2024 A | 6331 | 0 | 0 | $0 |
| Charles O Holliday JR | مدير | 25 إبريل، 2022 A | 18955 | 0 | 0 | $0 |
| Geoffrey G Meyers | مدير | 1 مايو، 2019 A | 39153 | 0 | 0 | $0 |
| John W Rowe | مدير | 1 مايو، 2019 A | 30388 | 0 | 0 | $0 |
| Ann H Lamont | مدير | 2 مايو، 2018 A | 17661 | 0 | 0 | $0 |
| Jay O Light | مدير | 3 مايو، 2017 A | 30953 | 0 | 0 | $0 |
| Stephen G Pagliuca | مدير | 5 ديسمبر، 2014 D | 7612921 | 0 | 0 | $0 |
| Christopher R Gordon | مدير | 1 نوفمبر، 2013 D | 30003156 | 0 | 0 | $0 |
| John Connaughton | مدير | 1 نوفمبر، 2013 D | 30003156 | 0 | 0 | $0 |
| John H Mcarthur | مدير | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| Kent C Nelson | مدير | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| Magdalena Averhoff MD | مدير | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| Glenda A Hatchett | مدير | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| Frederick W Gluck | مدير | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| Harold T Shapiro | مدير | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| Michael C Armstrong | مدير | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| Martin Feldstein | مدير | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| Michael T Long | مدير | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| ROYAL FRANK S | مدير | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| Patricia F Elcan | مالك 10% | 6 فبراير، 2026 J | 36557141 | 0 | 0 | $0 |
| Frisco Holding II | مالك 10% | 6 فبراير، 2026 J | 36557141 | 0 | 0 | $0 |
| HERCULES HOLDING II, LLC | مالك 10% | 6 فبراير، 2026 J | 32282889 | 0 | 0 | $0 |
| Thomas F Frist JR | مالك 10% | 6 فبراير، 2026 J | 36557141 | 0 | 0 | $0 |
| Patricia C Frist | مالك 10% | 20 فبراير، 2018 G | 0 | 0 | 0 | $0 |
| KKR PEI GP LTD | مالك 10% | 1 إبريل، 2014 J | 0 | 0 | 0 | $0 |
| Jonathan B Perlin | · | 2 أغسطس، 2021 S | 44348 | 0 | 0 | $0 |
| Juan Vallarino | · | 9 مايو، 2016 M | 61036 | 0 | 0 | $0 |
| Richard M Bracken | · | 31 ديسمبر، 2014 F | 82499 | 0 | 0 | $0 |
| BANK OF AMERICA CORP /DE/ | · | 6 نوفمبر، 2012 S | 2652364 | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 141 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| BUL · Pacer Funds Trust | 5,07% | 16545 NS | 31 يوليو، 2026 | N-PORT |
| IHF · iShares Trust | 4,75% | 147977 SH | 11 سبتمبر، 2026 | يومي |
| STNC · Hennessy Funds Trust | 3,17% | 7315 NS | 31 يوليو، 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 2,50% | 97403 SH | 1 أكتوبر، 2026 | يومي |
| COWZ · Pacer Funds Trust | 2,07% | 960711 NS | 31 يوليو، 2026 | N-PORT |
| WLTG · ETF Opportunities Trust | 2,06% | 3942 NS | 31 يوليو، 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,65% | 33803 SH | 1 أكتوبر، 2026 | يومي |
| RPG · Invesco Exchange-Traded Fund Trust | 1,30% | 58562 SH | 1 أكتوبر، 2026 | يومي |
| FLAG · Global X Funds | 1,14% | 48 NS | 31 يوليو، 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1,03% | 6909 NS | 31 يوليو، 2026 | N-PORT |
| IYH · iShares Trust | 1,01% | 87417 SH | 11 سبتمبر، 2026 | يومي |
| SRHQ · Elevation Series Trust | 0,94% | 4938 NS | 31 يوليو، 2026 | N-PORT |
| NEAR · iShares U.S. ETF Trust | 0,92% | 48109000 SH | 11 سبتمبر، 2026 | يومي |
| FHLC · FIDELITY COVINGTON TRUST | 0,91% | 74445 NS | 31 يوليو، 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,90% | 470451 SH | 19 أغسطس، 2026 | يومي |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,87% | 22725 NS | 31 يوليو، 2026 | N-PORT |
| DIVB · iShares Trust | 0,87% | 42100 SH | 11 سبتمبر، 2026 | يومي |
| NFRA · FlexShares Trust | 0,84% | 62628 NS | 31 يوليو، 2026 | N-PORT |
| IXJ · iShares Trust | 0,83% | 81708 SH | 11 سبتمبر، 2026 | يومي |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,81% | 2483 SH | 1 أكتوبر، 2026 | يومي |
| QUVU · Hartford Funds Exchange-Traded Trust | 0,79% | 3522 NS | 31 يوليو، 2026 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,78% | 23458000 | 1 أكتوبر، 2026 | يومي |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0,74% | 25897000 | 1 أكتوبر، 2026 | يومي |
| CURE · Direxion Shares ETF Trust | 0,72% | 3056 NS | 31 يوليو، 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,67% | 12075 SH | 19 أغسطس، 2026 | يومي |
| LGDX · Tidal Trust III | 0,66% | 2345 NS | 31 يوليو، 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,55% | 11876 SH | 19 أغسطس، 2026 | يومي |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0,50% | 22893000 | 1 أكتوبر، 2026 | يومي |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,46% | 7404 NS | 31 يوليو، 2026 | N-PORT |
| WLDR · Two Roads Shared Trust | 0,43% | 964 NS | 31 يوليو، 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,42% | 7289 NS | 31 يوليو، 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,41% | 92254 SH | 1 أكتوبر، 2026 | يومي |
| QLC · FlexShares Trust | 0,39% | 9856 NS | 31 يوليو، 2026 | N-PORT |
| XOEF · iShares Trust | 0,37% | 194 SH | 11 سبتمبر، 2026 | يومي |
| GSY · Invesco Actively Managed Exchange-T… | 0,36% | 14000000 | 1 أكتوبر، 2026 | يومي |
| UPSD · ETF Series Solutions | 0,33% | 972 NS | 31 يوليو، 2026 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,33% | 9324000 | 1 أكتوبر، 2026 | يومي |
| MGV · VANGUARD WORLD FUND | 0,29% | 97604 SH | 19 أغسطس، 2026 | يومي |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0,28% | 390000 | 1 أكتوبر، 2026 | يومي |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,28% | 3186 NS | 31 يوليو، 2026 | N-PORT |
| USXF · iShares Trust | 0,26% | 9226 SH | 11 سبتمبر، 2026 | يومي |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,26% | 5803 SH | 1 أكتوبر، 2026 | يومي |
| IWX · iShares Trust | 0,23% | 21535 SH | 11 سبتمبر، 2026 | يومي |
| VTV · VANGUARD INDEX FUNDS | 0,23% | 1475731 SH | 19 أغسطس، 2026 | يومي |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,23% | 14235 NS | 31 يوليو، 2026 | N-PORT |
| MPLY · Strategy Shares | 0,22% | 87 NS | 31 يوليو، 2026 | N-PORT |
| EUSA · iShares, Inc. | 0,21% | 9589 SH | 11 سبتمبر، 2026 | يومي |
| RSP · Invesco Exchange-Traded Fund Trust | 0,21% | 463744 SH | 1 أكتوبر، 2026 | يومي |
| FTC · First Trust Exchange-Traded AlphaDE… | 0,20% | 6420 NS | 31 يوليو، 2026 | N-PORT |
| SIZE · iShares Trust | 0,19% | 1920 SH | 11 سبتمبر، 2026 | يومي |
| DYNF · BlackRock ETF Trust | 0,19% | 183934 SH | 11 سبتمبر، 2026 | يومي |
| VMAX · Lattice Strategies Trust | 0,19% | 228 NS | 31 يوليو، 2026 | N-PORT |
| DSI · iShares Trust | 0,19% | 23734 SH | 11 سبتمبر، 2026 | يومي |
| ILCV · iShares Trust | 0,18% | 5870 SH | 10 سبتمبر، 2026 | يومي |
| IVW · iShares Trust | 0,18% | 331185 SH | 11 سبتمبر، 2026 | يومي |
| IUSG · iShares Trust | 0,17% | 136713 SH | 11 سبتمبر، 2026 | يومي |
| VOOG · VANGUARD ADMIRAL FUNDS | 0,17% | 115334 SH | 19 أغسطس، 2026 | يومي |
| IWD · iShares Trust | 0,17% | 332035 SH | 11 سبتمبر، 2026 | يومي |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,16% | 17845 SH | 1 أكتوبر، 2026 | يومي |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,16% | 90157 SH | 19 أغسطس، 2026 | يومي |
| USMV · iShares Trust | 0,16% | 89855 SH | 11 سبتمبر، 2026 | يومي |
| ACWV · iShares, Inc. | 0,15% | 11903 SH | 11 سبتمبر، 2026 | يومي |
| EGLE · Global X Funds | 0,15% | 8 NS | 31 يوليو، 2026 | N-PORT |
| GLBL · Pacer Funds Trust | 0,15% | 4 NS | 31 يوليو، 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0,15% | 33327 SH | 1 أكتوبر، 2026 | يومي |
| VOXP · Advisors Series Trust | 0,13% | 18 NS | 31 يوليو، 2026 | N-PORT |
| VRIG · Invesco Actively Managed Exchange-T… | 0,12% | 2250000 | 1 أكتوبر، 2026 | يومي |
| TOPC · iShares Trust | 0,12% | 95 SH | 11 سبتمبر، 2026 | يومي |
| DGRO · iShares Trust | 0,12% | 120741 SH | 11 سبتمبر، 2026 | يومي |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,11% | 4392 SH | 1 أكتوبر، 2026 | يومي |
| XVV · iShares Trust | 0,11% | 1790 SH | 11 سبتمبر، 2026 | يومي |
| IWL · iShares Trust | 0,11% | 5786 SH | 11 سبتمبر، 2026 | يومي |
| MGC · VANGUARD WORLD FUND | 0,11% | 31176 SH | 19 أغسطس، 2026 | يومي |
| ACIO · ETF Series Solutions | 0,11% | 6205 NS | 31 يوليو، 2026 | N-PORT |
| EVUS · iShares Trust | 0,10% | 934 SH | 11 سبتمبر، 2026 | يومي |
| ADME · ETF Series Solutions | 0,10% | 751 NS | 31 يوليو، 2026 | N-PORT |
| XRMI · Global X Funds | 0,10% | 126 NS | 31 يوليو، 2026 | N-PORT |
| XCLR · Global X Funds | 0,10% | 9 NS | 31 يوليو، 2026 | N-PORT |
| XYLD · Global X Funds | 0,10% | 8148 NS | 31 يوليو، 2026 | N-PORT |
| XTR · Global X Funds | 0,10% | 12 NS | 31 يوليو، 2026 | N-PORT |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,10% | 26763 SH | 1 أكتوبر، 2026 | يومي |
| BKLC · BNY Mellon ETF Trust | 0,10% | 13621 NS | 31 يوليو، 2026 | N-PORT |
| VV · VANGUARD INDEX FUNDS | 0,10% | 181364 SH | 19 أغسطس، 2026 | يومي |
| ESGV · VANGUARD WORLD FUND | 0,10% | 33758 SH | 19 أغسطس، 2026 | يومي |
| IVV · iShares Trust | 0,10% | 1957485 SH | 11 سبتمبر، 2026 | يومي |
| PTLC · Pacer Funds Trust | 0,10% | 7919 NS | 31 يوليو، 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,10% | 1395 NS | 31 يوليو، 2026 | N-PORT |
| PBP · Invesco Exchange-Traded Fund Trust | 0,10% | 877 SH | 1 أكتوبر، 2026 | يومي |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,10% | 1791 SH | 1 أكتوبر، 2026 | يومي |
| ILCB · iShares Trust | 0,10% | 2915 SH | 11 سبتمبر، 2026 | يومي |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,09% | 20766 NS | 31 يوليو، 2026 | N-PORT |
| IYY · iShares Trust | 0,09% | 6693 SH | 11 سبتمبر، 2026 | يومي |
| VOTE · TCW ETF Trust | 0,09% | 2545 NS | 31 يوليو، 2026 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,09% | 3614 NS | 31 يوليو، 2026 | N-PORT |
| XYLG · Global X Funds | 0,09% | 147 NS | 31 يوليو، 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,09% | 46791 NS | 31 يوليو، 2026 | N-PORT |
| IWB · iShares Trust | 0,09% | 103721 SH | 11 سبتمبر، 2026 | يومي |
| VOO · VANGUARD INDEX FUNDS | 0,09% | 4034357 SH | 19 أغسطس، 2026 | يومي |
| TOV · EA Series Trust | 0,09% | 607 NS | 31 يوليو، 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0,09% | 586 NS | 31 يوليو، 2026 | N-PORT |
| ITOT · iShares Trust | 0,09% | 202387 SH | 11 سبتمبر، 2026 | يومي |
| ACVF · ETF Opportunities Trust | 0,09% | 337 NS | 31 يوليو، 2026 | N-PORT |
| GTOS · Invesco Actively Managed Exchange-T… | 0,09% | 104000 | 1 أكتوبر، 2026 | يومي |
| QDPL · Pacer Funds Trust | 0,09% | 3708 NS | 31 يوليو، 2026 | N-PORT |
| IWV · iShares Trust | 0,09% | 41034 SH | 11 سبتمبر، 2026 | يومي |
| DFAU · Dimensional ETF Trust | 0,08% | 25516 NS | 31 يوليو، 2026 | N-PORT |
| CRBN · iShares Trust | 0,08% | 2269 SH | 11 سبتمبر، 2026 | يومي |
| PHDG · Invesco Actively Managed Exchange-T… | 0,08% | 116 SH | 1 أكتوبر، 2026 | يومي |
| TOK · iShares Trust | 0,08% | 451 SH | 11 سبتمبر، 2026 | يومي |
| VTI · VANGUARD INDEX FUNDS | 0,08% | 4930930 SH | 19 أغسطس، 2026 | يومي |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,08% | 24633 SH | 19 أغسطس، 2026 | يومي |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,08% | 12577 SH | 19 أغسطس، 2026 | يومي |
| HCMT · Direxion Shares ETF Trust | 0,08% | 1081 NS | 31 يوليو، 2026 | N-PORT |
| TILT · FlexShares Trust | 0,08% | 4108 NS | 31 يوليو، 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0,07% | 12141 NS | 31 يوليو، 2026 | N-PORT |
| URTH · iShares, Inc. | 0,07% | 14079 SH | 11 سبتمبر، 2026 | يومي |
| ACWI · iShares Trust | 0,06% | 50294 SH | 11 سبتمبر، 2026 | يومي |
| HDUS · Lattice Strategies Trust | 0,05% | 275 NS | 31 يوليو، 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,05% | 125729 SH | 19 أغسطس، 2026 | يومي |
| DCOR · Dimensional ETF Trust | 0,05% | 3816 NS | 31 يوليو، 2026 | N-PORT |
| GLOF · iShares Trust | 0,04% | 202 SH | 11 سبتمبر، 2026 | يومي |
| DUHP · Dimensional ETF Trust | 0,04% | 10761 NS | 31 يوليو، 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,02% | 28662 NS | 31 يوليو، 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,02% | 1127 NS | 31 يوليو، 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,01% | 99 NS | 31 يوليو، 2026 | N-PORT |
| GTO · Invesco Actively Managed Exchange-T… | 0,00% | 42000 | 30 سبتمبر، 2026 | يومي |
| CBLS · Elevation Series Trust | -1,12% | -1546 NS | 31 يوليو، 2026 | N-PORT |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 15 يوليو، 2026 | يومي |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | 15 يوليو، 2026 | يومي |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 15 يوليو، 2026 | يومي |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 15 يوليو، 2026 | يومي |
| VUSB · VANGUARD BOND INDEX FUNDS | · | · | 15 يوليو، 2026 | يومي |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 15 يوليو، 2026 | يومي |
| VPLS · VANGUARD MALVERN FUNDS | · | · | 15 يوليو، 2026 | يومي |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 15 يوليو، 2026 | يومي |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 15 يوليو، 2026 | يومي |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 يوليو، 2026 | يومي |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 يوليو، 2026 | يومي |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 30 يوليو، 2026 | يومي |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 30 يوليو، 2026 | يومي |
| VCEB · VANGUARD WORLD FUND | · | · | 30 يوليو، 2026 | يومي |
HCA توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
السعر المستهدف لمدة 12 شهرًا
22 محللين · 2026-09-28السعر المستهدف المتوسط $454.23 +6,5%
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
أساس السنة المالية، الأسعار كما في إغلاق نهاية السنة المالية الأخيرة لكل شركة.
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| HCA | $104.86B | 16.5 | 7.1% | 9.0% | -159.1% | · |
| THC | $17.28B | 12.8 | 3.1% | 11.1% | 56.4% | · |
| EHC | $10.61B | 19.2 | 10.5% | 9.5% | 25.1% | · |
| UHS | · | 9.4 | 9.7% | 8.6% | 21.4% | · |
| ENSG | $10.12B | 29.8 | 18.7% | 6.8% | 16.9% | · |
| PACS | $6.01B | 31.5 | 29.3% | 3.6% | 23.1% | · |
| CON | $2.53B | 15.1 | 13.9% | 7.7% | 49.8% | · |
| BKD | $2.57B | -9.6 | 2.2% | -8.2% | -313.2% | 26.2% |
| ACHC | $1.28B | -1.2 | 5.0% | -33.3% | -43.9% | · |
| SNDA | $612M | -7.7 | 25.2% | -18.6% | -197.2% | · |
آخر الأخبار أحدث العناوين التي تذكر هذه الشركة
إشارات التداول إشارات شراء/بيع حديثة مع سعر الدخول ونسبة المخاطرة/المكافأة
لا توجد إشارة مفتوحة حاليًا — لا توجد بطاقة معبأة، وهذا أمر صادق.
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
اختر المقاييس التي تهمك — انقر فوق علامة + بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.